



October 23, 2014

Alva M. Lambert, Esq.
Executive Director
State Health Planning & Development Agency
100 North Union St., Suite 870
Montgomery AL 36104

Jennifer H. Clark
Direct: (205) 521-8020
Fax: (205) 488-6020
jclark@babc.com

RECEIVED

OCT 24 2014

STATE HEALTH PLANNING
AND DEVELOPMENT AGENCY

RE: Request for Reviewability Determination
Bio-Medical Applications of Alabama, Inc. d/b/a Fresenius Medical Care
Tallassee

Dear Mr. Lambert:

The purpose of this letter is to request your determination, pursuant to Section 401-1-7-.02 of the Alabama Certificate of Need Program Rules & Regulations ("Regulations"), that the proposed establishment of a new end stage renal disease treatment center and operation of ten (10) stations in Elmore County, Alabama, does not require our client, Bio-Medical Applications of Alabama, Inc. d/b/a Fresenius Medical Care Tallassee ("Fresenius"), to obtain a Certificate of Need ("CON") from the State Health Planning and Development Agency. Attached is a check for \$1,000.00 in payment for the applicable fee. In order to assist with this determination, we offer the following information:

Pursuant to Ala. Code § 22-21-278, a kidney disease treatment center located in a Class 3, 4, 5, 6, 7, or 8 municipality, as defined by Ala. Code § 11-40-12(a), which contains no more than ten (10) freestanding hemodialysis stations is not subject to CON review. However, this exemption from the CON program does not apply to a dialysis facility located in a Class 4, 5, 6, 7, or 8 municipality if such municipality, or any part of such municipality, is located in a county in which a Class 1, 2, or 3 municipality, or any part thereof, is located.

The proposed location of Fresenius Medical Care Tallassee is in Elmore County, Alabama, with the end stage renal disease treatment center to be located in Tallassee. Elmore County does not contain a Class 1, 2, or 3 municipality¹ and, accordingly, the Elmore County proposal meets the exemption criteria set forth in Ala. Code § 22-21-278, which provides, in pertinent part, as follows:

(b) Notwithstanding any existing law to the contrary, any kidney disease treatment center that contains no more than ten freestanding hemodialysis units and that is located in a Class 3, 4, 5, 6, 7 or 8

¹ As defined by Section 11-40-12(a), a Class 1 municipality is a city with a population of 300,000 inhabitants or more; a Class 2 municipality is a city with a population of not less than 175,000, and not more than 299,999 inhabitants; and a Class 3 municipality is a city with a population of not less than 100,000, and not more than 174,999 inhabitants.


municipality (as such classes are defined in Section s11-40-12 and 11-40-13 or any successor provision of law) **shall not be subject to or governed by the provisions of Article 9 of Chapter 21 of Title 22** (including, without limitation, the provision of said articles which require that a certificate of need be obtained from the State Health Planning and Development Agency as a condition precedent to the offering or development of new institutional health services).

- (c) The provisions of subsection (b) shall not apply to a kidney disease treatment center located in a Class 4, 5, 6, 7 or 8 municipality if such municipality or any part thereof is located in a county in which a Class 1, 2 or 3 municipality or any part thereof is located. [emphasis added]

Therefore, pursuant to Ala. Code § 22-21-278 and Ala. Admin. Code § 410-2-3-.05(1)(b), a CON is not required for the proposed project.

Based upon the above, we respectfully request your determination that Fresenius is exempt from CON review and is not required to obtain a CON in order to complete the project as described in this letter. We appreciate your consideration of this request, and welcome the opportunity to address any questions regarding this matter. Thank you very much.

Best regards,



Jennifer H. Clark